Premium
Reprogramming Tumor Associated Macrophages toward M1 Phenotypes with Nanomedicine for Anticancer Immunotherapy
Author(s) -
Xu Xiaoxuan,
Gong Xiang,
Wang Yuqi,
Li Jie,
Wang Hong,
Wang Jiaoying,
Sha Xianyi,
Li Yaping,
Zhang Zhiwen
Publication year - 2020
Publication title -
advanced therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.125
0ISSN - 2366-3987
DOI - 10.1002/adtp.201900181
Subject(s) - reprogramming , immunotherapy , tumor microenvironment , cancer research , nanomedicine , cancer immunotherapy , phenotype , tumor associated macrophage , immune system , tumor cells , medicine , immunology , biology , cell , nanotechnology , materials science , biochemistry , genetics , nanoparticle , gene
Tumor‐associated macrophages (TAMs), one of the most important constituents in tumor immunosuppressive microenvironments, are a potential therapeutic target due to their essential role in promoting tumor progression and metastasis. Macrophages are usually divided into two categories of protumoral M2‐like TAMs and antitumoral M1 phenotypes at the two extremes. Reprogramming M2‐like TAMs toward tumoricidal M1 phenotype is especially intriguing in terms of the restoration of antitumor immunity for anticancer immunotherapy. In this review, the recent advances of nanomedicine‐mediated reprogramming of TAMs from M2 to M1 to elicit the antitumor immunity are discussed. This reprogramming can be achieved via direct re‐education by targeted delivery of various active agents to TAMs and indirect re‐education by modulating the abnormal tumor microenvironment. Perspectives on nanomedicine mediated TAMs‐M1 reprogramming for effective anticancer immunotherapy are also presented.